These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 19286755

  • 1. Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment.
    Labiós M, Martínez M, Gabriel F, Guiral V, Dasi F, Beltrán B, Muñoz A.
    J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):24-30. PubMed ID: 19286755
    [Abstract] [Full Text] [Related]

  • 2. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
    Labiós M, Martínez M, Gabriel F, Guiral V, Ruiz-Aja S, Beltrán B, Muñoz A.
    J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
    [Abstract] [Full Text] [Related]

  • 3. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
    Labiós M, Martínez M, Gabriel F, Guiral V, Munoz A, Aznar J.
    Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
    [Abstract] [Full Text] [Related]

  • 4. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
    Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of the ESTEPP Study.
    Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
    [Abstract] [Full Text] [Related]

  • 6. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
    Drugs Exp Clin Res; 2004 Apr; 30(3):125-32. PubMed ID: 15366789
    [Abstract] [Full Text] [Related]

  • 7. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nádházi Z, Petrella R, Sedefdjian A, Sévenier F, Shlyakhto EV, Pathak A.
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of eprosartan in diabetic hypertensive patients.
    Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of ESTEPP Study.
    Eur J Intern Med; 2008 Jan; 19(1):27-31. PubMed ID: 18206598
    [Abstract] [Full Text] [Related]

  • 9. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity.
    Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB.
    Am J Hypertens; 2006 Feb; 19(2):214-9. PubMed ID: 16448896
    [Abstract] [Full Text] [Related]

  • 10. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
    Voors AA, van de Wal RM, Hartog JW, Vijn RG, Hummel YM, Plokker TW, van Veldhuisen DJ, Jaarsma W.
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
    [Abstract] [Full Text] [Related]

  • 11. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
    Pathak A, Hanon O, Negre-Pages L, Sevenier F, OSCAR investigators.
    Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 13. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [Abstract] [Full Text] [Related]

  • 14. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 15. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 16. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA, Choueiry P, Ismail A, Eid E, Berrou JP, Sedefdjian A, Sévenier F, Pathak A.
    Vasc Health Risk Manag; 2011 Nov; 7():491-5. PubMed ID: 21915165
    [Abstract] [Full Text] [Related]

  • 17. [Activity of intracellular antioxidant enzymes in hypertensive patients].
    El'chaninova SA, Galaktionova LP, Tolmacheva NV, Varshavskiĭ BIa.
    Ter Arkh; 2000 Nov; 72(4):51-3. PubMed ID: 10833800
    [Abstract] [Full Text] [Related]

  • 18. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA, Nuñez JF, Domínguez-Gil A, MEFASA Group.
    Drugs Aging; 2009 Nov; 26(7):617-26. PubMed ID: 19655828
    [Abstract] [Full Text] [Related]

  • 19. [Elevation pressure in morning hours in patients with essential hypertension: effect therapy with eprosartan for leading stress tests].
    Shevchenko OP, Praskurnichiĭ EA, Makarova SV, Samartsev GA, Lapina EIa.
    Kardiologiia; 2004 Nov; 44(3):58-63. PubMed ID: 15489829
    [No Abstract] [Full Text] [Related]

  • 20. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group.
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.